Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA oncol. 2016;2:1346–53.

Article  PubMed  Google Scholar 

Wang DY, Ye F, Zhao S, et al. Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: a systematic review and meta-analysis. Oncoimmunology. 2017;6: e1344805.

Article  PubMed  PubMed Central  Google Scholar 

Haanen J, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017; 28:iv119-iv142

Abu-Sbeih H, Ali FS, Alsaadi D, et al. Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor-induced colitis: a multi-center study. J Immunother Cancer. 2018;6:142.

Article  PubMed  PubMed Central  Google Scholar 

Soularue E, Lepage P, Colombel J, et al. Enterocolitis due to immune checkpoint inhibitors: a systematic review. Gut. 2018;67:2056–67.

Article  CAS  PubMed  Google Scholar 

Abu-Sbeih H, Ali FS, Qiao W, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. Cancer Immunol Immunother. 2019;68:553–61.

Article  CAS  PubMed  Google Scholar 

Gupta A, De Felice KM, Loftus EV Jr. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015;42:406–17.

Article  CAS  PubMed  Google Scholar 

Abu-Sbeih H, Ali FS, Wang X, et al. Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis. J Immunother Cancer. 2019;7:93.

Article  PubMed  PubMed Central  Google Scholar 

Som A, Mandaliya R, Alsaadi D, et al. Immune checkpoint inhibitor-induced colitis: a comprehensive review. World J Clin Cases. 2019;7:405–18.

Article  PubMed  PubMed Central  Google Scholar 

Ibraheim H, Baillie S, Samaan MA, et al. Systematic review with meta-analysis: effectiveness of anti-inflammatory therapy in immune checkpoint inhibitor-induced enterocolitis. Aliment Pharmacol Ther. 2020;52:1432–52.

Article  CAS  PubMed  Google Scholar 

Burla J, Bluemel S, Biedermann L, et al. Retrospective analysis of treatment and complications of immune checkpoint inhibitor-associated colitis: Histological ulcerations as potential predictor for a steroid-refractory disease course. Inflamm Intest Dis. 2020;5:109–16.

Article  PubMed  PubMed Central  Google Scholar 

Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn’s disease. N Engl J Med. 2013;369:711–21.

Article  CAS  PubMed  Google Scholar 

Colombel JF, Sands BE, Rutgeerts P, et al. The safety of vedolizumab for ulcerative colitis and Crohn’s disease. Gut. 2017;66:839–51.

Article  CAS  PubMed  Google Scholar 

Diana P, Mankongpaisarnrung C, Atkins MB, et al. Emerging role of vedolizumab in managing refractory immune checkpoint inhibitor-induced enteritis. ACG Case Rep J. 2018;5: e17.

Article  PubMed  PubMed Central  Google Scholar 

Randhawa M, Gaughran G, Archer C, et al. Vedolizumab in combined immune checkpoint therapy-induced infliximab-refractory colitis in a patient with metastatic melanoma: A case report. World J Clin Oncol. 2019;10:350–7.

Article  PubMed  PubMed Central  Google Scholar 

Rodriguez-Lago I, Benitez JM, Sempere L, et al. The combination of granulocyte-monocyte apheresis and vedolizumab: a new treatment option for ulcerative colitis? J Clin Apher. 2019;34:680–5.

Article  PubMed  Google Scholar 

Sakuraba A, Motoya S, Watanabe K, et al. An open-label prospective randomized multicenter study shows very rapid remission of ulcerative colitis by intensive granulocyte and monocyte adsorptive apheresis as compared with routine weekly treatment. Am J Gastroenterol. 2009;104:2990–5.

Article  PubMed  Google Scholar 

Yokoyama Y, Kawai Y, Fukunaga K, et al. Looking for predictive factors of clinical response to adsorptive granulocyte and monocyte apheresis in patients with ulcerative colitis: markers of response to GMA. BMC Gastroenterol. 2013;13:27.

Article  PubMed  PubMed Central  Google Scholar 

Alissafi T, Hatzioannou A, Legaki AI, et al. Balancing cancer immunotherapy and immune-related adverse events: the emerging role of regulatory T cells. J Autoimmun. 2019;104: 102310.

Article  CAS  PubMed  Google Scholar 

Nagase K, Fukunaga K, Kashiwamura S, et al. Immunoregulatory effects of adsorptive granulocyte and monocyte apheresis in patients with drug refractory Crohn’s disease. Ther Apher Dial. 2011;15:367–73.

Article  CAS  PubMed  Google Scholar